MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/ebm.2026.10709

Медицинская библиотека · The American journal of managed care · 2008

Medicare capitation model, functional status, and multiple comorbidities: model accuracy.

Sriphoosanaphan Supachaya, Thanapirom Kessarin, Kerr Stephen J, Suksawatamnuay Sirinporn, Thaimai Panarat, Sittisomwong Sukanya, Sonsiri Kanokwan, Srisoonthorn Nunthiya, Teeratorn Nicha, Tanpowpong Natthaporn, Chaopathomkul Bundit, Treeprasertsuk Sombat, Poovorawan Yong, Komolmit Piyawat

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

Replacement of vitamin D (VD) among patients with chronic hepatitis C (CHC) before viral eradication has demonstrated a protective effect on serum markers associated with hepatic fibrogenesis. We therefore hypothesized that VD may facilitate further fibrosis amelioration following curative treatment with direct-acting antivirals (DAA).

METHODS

This study was a randomized, double-blind, placebo-controlled trial conducted between February 2018 and August 2018. Patients with CHC and VD deficiency were randomized in a 1:1 ratio to either receive ergicalciferol or placebo over 6 weeks. Biochemical analysis indicators, including 25-hydroxyvitamin D (25(OH)D), fibrogenic markers [(transforming growth factor beta 1 (TGF-β1) and tissue inhibitors of matrix metalloproteinases 1 (TIMP-1)], and fibrolytic markers [matrix metalloproteinase 9 (MMP-9) and amino terminal type III procollagen peptide (P3NP)], were assessed at baseline and at 6 weeks. Serum 25(OH)D was analyzed by a chemiluminescence immunoassay. Serum hepatic fibrogenesis markers were measured using a quantitative sandwich enzyme-linked immunosorbent assay.

RESULTS

Seventy-five patients with CHC and VD deficiency were randomly assigned to VD (n = 37) and placebo (n = 38) groups. At the end of the study, the mean serum 25(OH)D level had risen to a normal level in the VD group, but was still deficient in the placebo group (41.8 ±   9.1 vs. 18.1 ±  4.6 ng/mL, p < 0.001). Upon restoration of the VD level, there were no significant mean differences in the change from baseline for TGF-β1 (-0.6 ng/mL (95% confidence interval (95% CI) [-2.8-1.7]), p = 0.63), TIMP-1 (-5.5 ng/mL (95% CI [-26.4 -15.3]), p = 0.60), MMP-9 (122.9 ng/mL (95% CI [-69.0 -314.8]), p = 0.21), and P3NP (-0.1 ng/mL (95% CI [-2.4 -2.2]), p = 0.92) between the VD and placebo groups.

CONCLUSION

Short-term VD supplementation after DAA treatment in patients with CHC does not improve serum fibrogenesis markers and may not expedite the residual liver fibrosis healing process. Future studies are warranted to evaluate the long-term effect of VD supplementation on hepatic fibrosis regression.

Для цитирования: Sriphoosanaphan Supachaya, Thanapirom Kessarin, Kerr Stephen J, Suksawatamnuay Sirinporn, Thaimai Panarat, Sittisomwong Sukanya, Sonsiri Kanokwan, Srisoonthorn Nunthiya, Teeratorn Nicha, Tanpowpong Natthaporn, Chaopathomkul Bundit, Treeprasertsuk Sombat, Poovorawan Yong, Komolmit Piyawat. Medicare capitation model, functional status, and multiple comorbidities: model accuracy.. The American journal of managed care. 2008. DOI: 10.3389/ebm.2026.10709.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.